Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, Robert J.; Tannir, Nizar M.; McDermott, David F.; Arén Frontera, Osvaldo; Melichar, Bohuslav; Choueiri, Toni K.; Plimack, Elizabeth R.; Barthélémy, Philippe; Porta, Camillo; George, Saby; Powles, Thomas; Donskov, Frede; Neiman, Victoria; Kollmannsberger, Christian K.; Salman, Pamela; Gurney, Howard; Hawkins, Robert; Ravaud, Alain; Grimm, Marc-Oliver; Bracarda, Sergio; Barrios, Carlos H.; Tomita, Yoshihiko; Castellano, Daniel; Rini, Brian I.; Chen, Allen C.; Mekan, Sabeen; McHenry, M. Brent; Wind-Rotolo, Megan; Doan, Justin; Sharma, Padmanee; Hammers, Hans J.; Escudier, Bernard

doi:10.1056/nejmoa1712126

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

BACKGROUND Nivolumab plus ipilimumab produced objective responses in patients with advanced renal‐cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear‐cell advanced renal‐cell carcinoma. METHODS We randomly assigned a…